The mycobacterial cell envelope-lipids

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 10, 2014, Pages

  Jackson, Mary ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOGALACTAN; ARABINOMANNAN; ETHAMBUTOL; FOSMIDOMYCIN; GLYCEROPHOSPHOLIPID; ISONIAZID; ISOPRENOID; LIPID; LIPOARABINOMANNAN; MANNOSE RECEPTOR; MENAQUINONE; MYCOLIC ACID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PEPTIDOGLYCAN; PYRAZINAMIDE; THIOACETAZONE; THIOLACTOMYCIN; TIOCARLIDE; TRIACYLGLYCEROL; LIPOPOLYSACCHARIDE; MEMBRANE LIPID; TERPENE;

ANTIGENICITY; ARTICLE; BACTERIAL MEMBRANE; BIOGENESIS; BIOLOGICAL ACTIVITY; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; ENVIRONMENTAL FACTOR; HIGH THROUGHPUT SCREENING; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INNER MEMBRANE; LIPID COMPOSITION; LIPOGENESIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTER MEMBRANE; PATHOGENESIS; PATHOGENICITY; PLASMODIUM FALCIPARUM; PROTEIN FUNCTION; TRANSCRIPTOMICS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

MYCOBACTERIUM TUBERCULOSIS;

CELL MEMBRANE; DRUG DESIGN; LIPOPOLYSACCHARIDES; MEMBRANE LIPIDS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; SIGNAL TRANSDUCTION; TERPENES;

EID: 84923784982     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021105     Document Type: Article

References (163)

1. Afonso-Barroso A, Clark SO, Williams A, Rosa GT, Nobrega C, Silva-Gomes S, Vale-Costa S, Ummels R, Stoker N, Movahedzadeh F, et al. 2012. Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses. Cell Microbiol 15: 660-674.
2. Alahari A, Trivelli X, Guerardel Y, Dover LG, Besra GS, Sacchettini JC, Reynolds RC, Coxon GD, Kremer L. 2007. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS ONE 2: e1343.
3. Arora P, Foster EL, Porcelli SA. 2013. CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis. Adv Exp Med Biol 783: 199-223.
4. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, Lisle G, Jacobs WR. 1994. Inha, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
5. Barry CE, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA, Yuan Y. 1998. Mycolic acids: Structure, biosynthesis and physiological functions. Prog Lipid Res 37: 143-179.
6. Bertozzi CR, Schelle MW. 2008. Sulfated metabolites from Mycobacterium tuberculosis: Sulfolipid-1 and beyond. In The mycobacterial cell envelope (ed. Daffe M, Reyrat J-M), pp. 291-304. ASM, Washington, DC.
7. Bhamidi S, Shi L, Chatterjee D, Belisle JT, Crick DC, McNeil MR. 2012. A bioanalytical method to determine the cell wall composition ofMycobacterium tuberculosis grown in vivo. Anal Biochem 421: 240-249.
8. Bhowruth V, Brown AK, Reynolds RC, Coxon GD, Mackay SP, Minnikin DE, Besra GS. 2006. Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis. Bioorg Med Chem Lett 16: 4743-4747.
9. Bhowruth V, Brown AK, Besra GS. 2008. Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FASII dehydratase enzyme Rv0636. Microbiology 154: 1866-1875.
10. Bloch H. 1950. Studies on the virulence of tubercle bacilli; isolation and biological properties of a constituent of virulent organisms. J Exp Med 91: 197-218.
11. Boucau J, Sanki AK, Voss BJ, Sucheck SJ, Ronning DR. 2009. A coupled enzymatic assay measuringMycobacterium tuberculosis antigen 85C enzymatic activity. Anal Biochem 385: 120-127.
12. Brennan PJ. 1988. Mycobacterium and other actinomycetes. In Microbial lipids (ed. Ratledge C, Wilkinson SG), pp. 203-298. Academic, London.
13. Brennan PJ, Nikaido H. 1995. The envelope of mycobacteria. Annu Rev Biochem 64: 29-63.
14. Britton WJ, Triccas JA. 2008. The constituents of the cell envelope and their impact on the host immune system. In The mycobacterial cell envelope (ed. Daffe M, Reyrat J-M), pp. 249-270. ASM, Washington, DC.
15. Brodin P, Poquet Y, Levillain F, Peguillet I, Larrouy-Maumus G, Gilleron M, Ewann F, Christophe T, Fenistein D, Jang J, et al. 2010. High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. PLoS Pathog 6: e1001100.
16. Camacho LR, Constant P, Raynaud C, Laneelle MA, Triccas JA, Gicquel B, Daffe M, Guilhot C. 2001. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem 276: 19845-19854.
17. Cardona P-J, Soto CY, Martin C, Gicquel B, Agusti G, Guirado E, Sirakova TD, Kolattukudy PE, Julian E, Luquin M. 2006. Neutral red reaction is related to virulence and cell wall methyl-branched lipids inMycobacterium tuberculosis. Microbes Infect 8: 183-190.
18. Chan CE, Zhao BZ, Cazenave-Gassiot A, Pang SW, Bendt AK, Wenk MR, Macary PA, Hanson BJ. 2013. Novel phage display-derived mycolic acid-specific antibodies with potential for tuberculosis diagnosis. J Lipid Res 54: 2924-2932.
19. Chapman TM, Bouloc N, Buxton RS, Chugh J, Lougheed KE, Osborne SA, Saxty B, Smerdon SJ, Taylor DL, Whalley D. 2012. Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity againstMycobacterium tuberculosis. Bioorg Med Chem Lett 22: 3349-3353.
20. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, et al. 2009. High content screening identifies decaprenyl-phosphoribose 20 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5: e1000645.
21. Constant P, Perez E, Malaga W, Laneelle MA, Saurel O, Daffe M, Guilhot C. 2002. Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex. Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frameshift mutation in the pks15/1 gene. J Biol Chem 277: 38148-38158.
22. Coxon GD, Craig D, Corrales RM, Vialla E, Gannoun-Zaki L, Kremer L. 2013. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. PloS ONE 8: e53162.
23. Daffe M, Laneelle M-A. 1988. Distribution of phthiocerol diester, phenolic mycosides and related compounds in mycobacteria. J Gen Microbiol 134: 2049-2055.
24. Daffe M, Draper P. 1998. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 39: 131-203.
25. Daffe M, Lacave C, Laneelle MA, Laneelle G. 1987. Structure of the major triglycosyl phenol-phthiocerol of Mycobacterium tuberculosis (strain Canetti). Eur J Biochem 167: 155-160.
26. Daffe M, McNeil MR, Brennan PJ. 1991. Novel type-specific lipooligosaccharides from Mycobacterium tuberculosis. Biochemistry 30: 378-388.
27. Daffe M, Crick DC, Jackson M. 2014. Genetics of capsular polysaccharides and cell envelope (glyco)lipids. Microbiol Spectrum 2: MGM2-0021-2013.
28. Daniel J, Deb C, Dubey VS, Sirakova TD, Abomoelak B, Morbidoni HR, Kolattukudy PE. 2004. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation inMycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol 186: 5017-5030.
29. Danilenko VN, Osolodkin DI, Lakatosh SA, Preobrazhenskaya MN, Shtil AA. 2011. Bacterial eukaryotic type serine-threonine protein kinases: From structural biology to targeted anti-infective drug design. Curr Top Med Chem 11: 1352-1369.
30. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M. 2012. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J Med Chem 55: 3739-3755.
31. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, et al. 2009. Menaquinone synthesis is critical for maintainingmycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72: 85-97.
32. Dhiman RK, Dinadayala P, Ryan GJ, Lenaerts AJ, Schenkel AR, Crick DC. 2011. Lipoarabinomannan localization and abundance during growth of Mycobacterium smegmatis. J Bacteriol 193: 5802-5809.
33. Draper P. 1998. The outer parts of the mycobacterial envelope as permeability barriers. Frontiers Biosci 3: D1253-D1261.
34. Dubnau E, Chan J, Raynaud C, Mohan VP, Laneelle M-A, Yu K, Quemard A, Smith I, Daffe M. 2000. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol 36: 630-637.
35. Elamin AA, Stehr M, Oehlmann W, Singh M. 2009. The mycolyltransferase 85A, a putative drug target of Mycobacterium tuberculosis: Development of a novel assay and quantification of glycolipid-status of the mycobacterial cell wall. J Microbiol Method 79: 358-363.
36. Favrot L, Grzegorzewicz AE, Lajiness DH, Marvin RK, Boucau J, Isailovic D, Jackson M, Ronning DR. 2013. Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nat Commun 4: 2748.
37. Ferreras JA, Stirrett KL, Lu X, Ryu JS, Soll CE, Tan DS, Quadri LE. 2008. Mycobacterial phenolic glycolipid virulence factor biosynthesis: Mechanism and small-molecule inhibition of polyketide chain initiation. Chem Biol 15: 51-61.
38. Fukuda T, Matsumura T, Ato M, Hamasaki M, Nishiuchi Y, Murakami Y, Maeda Y, Yoshimori T, Matsumoto S, Kobayashi K, et al. 2013. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. mBio 4: e00472-12.
39. Gagneux S, Small PM. 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7: 328-337.
40. Galandrin S, Guillet V, Rane RS, Leger M, Radha N, Eynard N, Das K, Balganesh TS, Mourey L, Daffe M, et al. 2013. Assay development for identifying inhibitors of the mycobacterial FadD32 activity. J Biomol Screen. 18: 576-587.
41. Gilleron M, Jackson M, Nigou J, Puzo G. 2008. Structure, activities and biosynthesis of the phosphatidyl-myo-inositol-based lipoglycans. In Themycobacterial cell envelope (ed. Daffe M, Reyrat J-M), pp. 75-105. ASM, Washington, DC.
42. Glickman MS. 2008. Cording, cord factors and trehalose dimycolate. In The mycobacterial cell envelope (ed. Daffe M, Reyrat J-M), pp. 63-73. ASM, Washington DC.
43. Glickman MS, Cox JS, Jacobs WR Jr, 2000. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 5: 717-727.
44. Gonzalo Asensio J, Maia C, Ferrer NL, Barilone N, Laval F, Soto CY, Winter N, Daffe M, Gicquel B, Martin C, et al. 2006. The virulence-associated two-component PhoPPhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem 281: 1313-1316.
45. Goren MB. 1990. Mycobacterial fatty acid esters of sugars and sulfosugars. In handbook of lipid research glycolipids, phosphoglycolipids and sulfoglycolipids (ed. Kates M), pp. 363-461. Plenum, New York.
46. Goren MB, Brennan PJ. 1979. Mycobacterial lipids: Chemistry and biologic activities. In Tuberculosis (ed. Youmans GP), pp. 63-193. W.B. Saunders, Philadelphia.
47. Goren MB, Brokl O, Schaefer WB. 1974a. Lipids of putative relevance to virulence in Mycobacterium tuberculosis: Phthiocerol dimycocerosate and the attenuation indicator lipid. Infect Immun 9: 150-158.
48. Goren MB, Brokl O, Schaefer WB. 1974b. Lipids of putative relevance to virulence in Mycobacterium tuberculosis: Correlation of virulence with elaboration of sulfatides and strongly acidic lipids. Infect Immun 9: 142-149.
49. Graham JE, Clark-Curtiss JE. 1999. Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci 96: 11554-11559.
50. Gratraud P, Surolia N, Besra GS, Surolia A, Kremer L. 2008. Antimycobacterial activity and mechanism of action of NAS-91. Antimicrob Agents Chemother 52: 1162-1166.
51. Grzegorzewicz AE, Pham H, Gundi VAKB, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SEM, Kordula kova J, et al. 2012a. Inhibition ofmycolic acid transport across theMycobacterium tuberculosis plasma membrane. Nat Chem Biol 8: 334-341.
52. Grzegorzewicz AE, Kordulakova J, Jones V, Born SE, Belardinelli JM, Vaquie A, Gundi VA, Madacki J, Slama N, Laval F, et al. 2012b. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J Biol Chem 287: 38434-38441.
53. Guenin-Mace L, Simeone R, Demangel C. 2009. Lipids of pathogenic Mycobacteria: Contributions to virulence and host immune suppression. Transbound Emerg Dis 56: 255-268.
54. Guerin ME, Kordulakova J, Alzari PM, Brennan PJ, Jackson M. 2010. Molecular basis of phosphatidyl-myo-inositol mannoside biosynthesis and regulation in mycobacteria. J Biol Chem 285: 33577-33583.
55. Guiard J, Collmann A, Garcia-Alles LF, Mourey L, Brando T, Mori L, Gilleron M, Prandi J, De Libero G, Puzo G. 2009. Fatty acyl structures of Mycobacterium tuberculosis sulfoglycolipid govern T cell response. J Immunol 182: 7030-7037.
56. Guilhot C, Chalut C, Daffe M. 2008. Biosynthesis and roles of phenolic glycolipids and related molecules in Mycobacterium tuberculosis. In The mycobacterial cell envelope (ed. Daffe M, Reyrat J-M), pp. 273-289. ASM,Washington, DC.
57. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Rottger S, Altmann KH, Cole ST. 2012. Towards a new tuberculosis drug: Pyridomycin-Nature’s isoniazid. EMBO Mol Med 4: 1032-1042.
58. He H, Oka S, Han YK, Yamamura Y, Kusunose E, Kusunose M, Yano I. 1991. Rapid serodiagnosis of human mycobacteriosis by ELISA using cord factor (trehalose-6,60-dimycolate) purified from Mycobacterium tuberculosis as antigen. FEMS Microbiol Immunol 3: 201-204.
59. Hoffmann C, Leis A, Niederweis M, Plitzko JM, Engelhardt H. 2008. Disclosure of the mycobacterial outer membrane: Cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci 105: 3963-3967.
60. Huet G, Constant P, Malaga W, Laneelle MA, Kremer K, van Soolingen D, Daffe M, Guilhot C. 2009. A lipid profile typifies the Beijing strains of Mycobacterium tuberculosis: Identification of a mutation responsible for a modification of the structures of phthiocerol dimycocerosates and phenolic glycolipids. J Biol Chem 284: 27101-27113.
61. Ioerger TR, O’Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, et al. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PloS ONE 8: e75245.
62. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, Kinoshita T, Akira S, Yoshikai Y, Yamasaki S. 2009. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J ExpMed 206: 2879-2888.
63. Ishizaki Y, Hayashi C, Inoue K, Igarashi M, Takahashi Y, Pujari V, Crick DC, Brennan PJ, Nomoto A. 2013. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J Biol Chem 288: 30309-30319.
64. Jackson M, Stadthagen G, Gicquel B. 2007. Long-chain multiple methyl-branched fatty acid-containing lipids of Mycobacterium tuberculosis: Biosynthesis, transport, regulation and biological activities. Tuberculosis 87: 78-86.
65. Jackson M, McNeil MR, Brennan PJ. 2013. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Future Microbiol 8: 855-875.
66. Jarlier V, Nikaido H. 1994.Mycobacterial cell wall: Structure and role in natural resistance to antibiotics. FEMSMicrobiol Lett 123: 11-18.
67. Julian E, Matas L, Perez A, Alcaide J, Laneelle MA, Luquin M. 2002. Serodiagnosis of tuberculosis: Comparison of immunoglobulin A (IgA) response to sulfolipid I with IgG and IgM responses to 2,3-diacyltrehalose, 2,3,6-triacyltrehalose, and cord factor antigens. J Clin Microbiol 40: 3782-3788.
68. Kanai K, Wiegeshaus E, Smith DW. 1970. Demonstration of mycolic acid and phthiocerol dimycocerosate in “in vivo grown tubercle bacilli”. Jpn J Med Sci Biol 23: 327-333.
69. Karakousis PC, Bishai WR, Dorman SE. 2004. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol 6: 105-116.
70. Kaur D, Guerin ME, Skovierova H, Brennan PJ, Jackson M. 2009. Chapter 2. Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv Appl Microbiol 69: 23-78.
71. Kordulakova J, Gilleron M, Mikusˇova K, Puzo G, Brennan PJ, Gicquel B, Jackson M. 2002. Definition of the first mannosylation step in phosphatidylinositol synthesis: PimA is essential for growth of mycobacteria. J Biol Chem 277: 31335-31344.
72. Krishnan N, Malaga W, Constant P, Caws M, Tran TH, Salmons J, Nguyen TN, Nguyen DB, Daffe M, Young DB, et al. 2011. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PloS ONE 6: e23870.
73. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, et al. 2012. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56: 324-331.
74. Lee W, Vanderven BC, Fahey RJ, Russell DG. 2013. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288: 6788-6800.
75. Lemassu A, Daffe M. 1994. Structural features of the exocellular polysaccharides of Mycobacterium tuberculosis. Biochem J 297: 351-357.
76. Li X, Liu N, Zhang H, Knudson SE, Slayden RA, Tonge PJ. 2010. Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: Novel antibacterial agents against Mycobacterium tuberculosis. Bioorg Med Chem Lett 20: 6306-6309.
77. Li X, Liu N, Zhang H, Knudson SE, Li HJ, Lai CT, Simmerling C, Slayden RA, Tonge PJ. 2011.CoA adducts of 4-oxo-4-phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis menaquinone biosynthesis pathway. ACS Med Chem Lett 2: 818-823.
78. Li C, Du Q, Deng W, Xie J. 2012. The biology of mycobacterium cord factor and roles in pathogen-host interaction. Crit Rev Eukaryot Gene Expr 22: 289-297.
79. Lougheed KE, Osborne SA, Saxty B, Whalley D, Chapman T, Bouloc N, Chugh J, Nott TJ, Patel D, Spivey VL, et al. 2011. Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents. Tuberculosis (Edinb) 91: 277-286.
80. Lu X, Zhang H, Tonge PJ, Tan DS. 2008. Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis. Bioorg Med Chem Lett 18: 5963-5966.
81. Lu X, Zhou R, Sharma I, Li X, Kumar G, Swaminathan S, Tonge PJ, Tan DS. 2012. Stable analogues of OSB-AMP: Potent inhibitors of MenE, the o-succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. Chem Biochem 13: 129-136.
82. Ly D, Kasmar AG, Cheng TY, de Jong A, Huang S, Roy S, Bhatt A, van Summeren RP, Altman JD, Jacobs WR, et al. 2013. CD1c tetramers detect ex vivo T cell responses to processed phosphomycoketide antigens. J Exp Med 210: 729-741.
83. Magnet S, Hartkoorn RC, Szekely R, Pato J, Triccas JA, Schneider P, Szantai-Kis C, Orfi L, Chambon M, Banfi D, et al. 2010. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb) 90: 354-360.
84. Makarov V, Manina G, Mikusˇova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, et al. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324: 801-804.
85. Mann FM, Peters RJ. 2012. Isotuberculosinol: The unusual case of an immunomodulatory diterpenoid from Mycobacterium tuberculosis. Med Chem Comm 3: 899-904.
86. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466.
87. Matsunaga I, Sugita M. 2012.Mycoketide: ACD1c-presented antigen with important implications inmycobacterial infection. Clin Dev Immunol 2012: 981821.
88. Mikusˇova K, Slayden RA, Besra GS, Brennan PJ. 1995. Biogenesis of themycobacterial cellwall and the site of action of ethambutol. Antimicrob Agents Chemother 39: 2484-2489.
89. Minnikin DE. 1982. Lipids: Complex lipids, their chemistry, biosynthesis and roles. In The biology of mycobacteria (ed. Ratledge C, Stanford J), pp. 95-184. Academic, London.
90. Molle V, Kremer L. 2010. Division and cell envelope regulation by Ser/Thr phosphorylation:Mycobacterium shows the way. Mol Microbiol 75: 1064-1077.
91. Morita YS, Velasquez R, Taig E, Waller RF, Patterson JH, Tull D, Williams SJ, Billman-Jacobe H, McConville MJ. 2005. Compartmentalization of lipid biosynthesis in mycobacteria. J Biol Chem 280: 21645-21652.
92. Morita YS, Sena CCB, Waller RF, Kurokawa K, Sernee MF, Nakatani F, Haites RE, Billman-Jacobe H, McConville MJ, Maeda Y, et al. 2006. PimE is a polyprenol-phosphate-mannose-dependent mannosyltransferase that transfers the fifth mannose of phosphatidylinositol mannoside in mycobacteria. J Biol Chem 281: 25143-25155.
93. Nambiar JK, Pinto R, Aguilo JI, Takatsu K, Martin C, Britton WJ, Triccas JA. 2012. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4þ T-cell memory. Eur J Immunol 42: 385-392.
94. Neyrolles O, Guilhot C. 2011. Recent advances in deciphering the contribution ofMycobacterium tuberculosis lipids to pathogenesis. Tuberculosis (Edinb) 91: 187-195.
95. North EJ, Jackson M, Lee RE. 2013. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. Curr Pharm Des (in press).
96. Obiol-Pardo C, Rubio-Martinez J, Imperial S. 2011. The methylerythritol phosphate (MEP) pathway for isoprenoid biosynthesis as a target for the development of new drugs against tuberculosis. Curr Med Chem 18: 1325-1338.
97. Ojha A, Anand M, Bhatt A, Kremer L, Jacobs WR Jr, Hatfull GF. 2005. GroEL1: A dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell 123: 861-873.
98. Ojha AK, Trivelli X, Guerardel Y, Kremer L, Hatfull GF. 2010. Enzymatic hydrolysis of trehalose dimycolate releases free mycolic acids during mycobacterial growth in biofilms. J Biol Chem 285: 17380-17389.
99. Ortalo-Magne A, Dupont MA, Lemassu A, Andersen AB, Gounon P, Daffe M. 1995.Molecular composition of the outermost capsular material of the tubercle bacillus. Microbiol 141: 1609-1620.
100. Ortalo-Magne A, Lemassu A, Laneelle MA, Bardou F, Silve G, Gounon P, Marchal G, Daffe M. 1996. Identification of the surface-exposed lipids on the cell envelopes of Mycobacterium tuberculosis and other mycobacterial species. J Bacteriol 178: 456-461.
101. Pan P, Tonge PJ. 2012. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr Top Med Chem 12: 672-693.
102. Parish T, Liu J, Nikaido H, Stoker NG. 1997. A Mycobacterium smegmatis mutant with a defective inositol monophosphate phosphatase gene homolog has altered cell envelope permeability. J Bacteriol 179: 7827-7833.
103. Passemar C, Arbues A, Malaga W, Mercier I, Moreau F, Lepourry L, Neyrolles O, Guilhot C, Astarie-Dequeker C. 2014. Multiple deletions in the polyketide synthase gene repertoire of Mycobacterium tuberculosis reveal functional overlap of cell envelope lipids in host-pathogen interactions. Cell Microbiol 16: 195-213.
104. Patterson JH, Waller RF, Jeevarajah D, Billman-Jacobe H, McConville MJ. 2003. Mannose metabolism is required for mycobacterial growth. Biochem J 372: 77-86.
105. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffe M, Emile JF, Marchou B, Cardona PJ, et al. 2008. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4: e1000204.
106. Phetsuksiri B, Baulard AR, Cooper A, Minnikin DE, Douglas JD, Besra GS, Brennan PJ. 1999. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother 43: 1042-1051.
107. Pitarque S, Herrmann JL, Duteyrat JL, Jackson M, Stewart GR, Lecointe F, Payre B, Schwartz O, Young DB, Marchal G, et al. 2005. Deciphering the molecular bases of Mycobacterium tuberculosis binding to the lectin DC-SIGN reveals an underestimated complexity. Biochem J 392: 615-624.
108. Pitarque S, Larrouy-Maumus G, Payre B, Jackson M, Puzo G, Nigou J. 2008. The immunomodulatory lipoglycans, lipoarabinomannan and lipomannan, are exposed at the mycobacterial cell surface. Tuberculosis 88: 560-565.
109. Poce G, Bates RH, Alfonso S, Cocozza M, Porretta GC, Ballell L, Rullas J, Ortega F, De Logu A, Agus E, et al. 2013. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PloS ONE 8: e56980.
110. Rajni, Rao N, Meena LS. 2011. Biosynthesis and virulent behavior of lipids produced byMycobacterium tuberculosis: LAM and Cord Factor: An overview. Biotechnol Res Int 2011: 274693.
111. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, Kaplan G, Barry CE III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431: 84-87.
112. Reed MB, Gagneux S, Deriemer K, Small PM, Barry CE. 2007. The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol 189: 2583-2589.
113. Remuinan MJ, Perez-Herran E, Rullas J, Alemparte C, Martinez-Hoyos M, Dow DJ, Afari J, Mehta N, Esquivias J, Jimenez E, et al. 2013. Tetrahydropyrazolo[1,5-a]pyrimidine- 3-carboxamide and N-benzyl-6’,7’-dihydrospiro [piperidine-4,4’-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PloS ONE 8: e60933.
114. Ren H, Dover LG, Islam ST, Alexander DC, Chen JM, Besra GS, Liu J. 2007. Identification of the lipooligosaccharide biosynthetic gene cluster from Mycobacterium marinum. Mol Microbiol 63: 1345-1359.
115. Rodriguez JE, Ramirez AS, Salas LP, Helguera-Repetto C, Gonzalez-y-Merchand J, Soto CY, Hernandez-Pando R. 2013. Transcription of genes involved in sulfolipid and polyacyltrehalose biosynthesis ofMycobacterium tuberculosis in experimental latent tuberculosis infection. PloS ONE 8: e58378.
116. Rousseau C, Neyrolles O, Bordat Y, Giroux S, Sirakova TD, Prevost M-C, Kolattukudy PE, Gicquel B, Jackson M. 2003a. Deficiency in mycolipenate- and mycosanoatederived acyltrehaloses enhances early interactions of Mycobacterium tuberculosis with host cells. Cell Microbiol 5: 405-415.
117. Rousseau C, Turner OC, Rush E, Bordat Y, Sirakova TD, Kolattukudy PE, Ritter S, Orme IM, Gicquel B, Jackson M. 2003b. Sulfolipid deficiency does not affect the virulence of Mycobacterium tuberculosis H37Rv in mice and guinea pigs. Infect Immun 71: 4684-4690.
118. Rousseau C, Winter N, Pivert E, Bordat Y, Neyrolles O, Ave P, Huerre M, Gicquel B, Jackson M. 2004. Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. Cell Microbiol 6: 277-287.
119. Russell DG. 2011. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 240: 252-268.
120. Russell DG, Mwandumba HC, Rhoades EE. 2002.Mycobacterium and the coat of many lipids. J Cell Biol 158: 421-426.
121. Ryan GJ, Hoff DR, Driver ER, Voskuil ML, Gonzalez-Juarrero M, Basaraba RJ, Crick DC, Spencer JS, Lenaerts AJ. 2010. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PloS ONE 5: e11108.
122. Sacksteder KA, Protopopova M, Barry CE III, Andries K, Nacy CA. 2012. Discovery and development of SQ109: A new antitubercular drug with a novel mechanism of action. Future Microbiol 7: 823-837.
123. Sakamoto K, Kim MJ, Rhoades ER, Allavena RE, Ehrt S, Wainwright HC, Russell DG, Rohde KH. 2013.Mycobacterial trehalose dimycolate reprograms macrophage global gene expression and activates matrix metalloproteinases. Infect Immun 81: 764-776.
124. Sambandan D, Dao DN, Weinrick BC, Vilcheze C, Gurcha SS, Ojha A, Kremer L, Besra GS, Hatfull GF, Jacobs WR. 2013. Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitiveMycobacterium tuberculosis. mBio 4: e00222-00213.
125. Sani M, Houben ENG, Geurtsen J, Pierson J, de Punder K, van Zon M, Wever B, Piersma SR, Jimenez CR, Daffe M, et al. 2010. Direct visualization by cryo-EM of the mycobacterial capsular layer: A labile structure containing ESX-1-secreted proteins. PLoS Pathog 6: e1000794.
126. Sanki AK, Boucau J, Ronning DR, Sucheck SJ. 2009. Antigen 85C-mediated acyl-transfer between synthetic acyl donors and fragments of the arabinan. Glycoconj J 26: 589-596.
127. Schlesinger LS, Azad AK, Torrelles JB, Roberts E, Vergne I, Deretic V. 2008. Determinants of phagocytosis, phagosome biogenesis and autophagy for Mycobacterium tuberculosis. In Handbook of tuberculosis: Immunology and cell biology (ed. Kaufmann SHE, Britton WJ), pp. 1-22. Wiley-VCH, Darmstadt, Germany.
128. Shahab FM, Kobarfard F, Shafaghi B, Dadashzadeh S. 2010. Preclinical pharmacokinetics of KBF611, a new antituberculosis agent in mice and rabbits, and comparison with thiacetazone. Xenobiotica 40: 225-234.
129. Shui G, Bendt AK, Jappar IA, Lim HM, Laneelle M, Herve M, Via LE, Chua GH, Bratschi MW, Zainul Rahim SZ, et al. 2012. Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Mol Med 4: 27-37.
130. Simonney N, Molina JM, Molimard M, Oksenhendler E, Perronne C, Lagrange PH. 1995. Analysis of the immunological humoral response to Mycobacterium tuberculosis glycolipid antigens (DAT, PGLTb1) for diagnosis of tuberculosis in HIV-seropositive and -seronegative patients. Eur J Clin Microbiol Infect Dis 14: 883-891.
131. Simonney N, Molina JM, Molimard M, Oksenhendler E, Lagrange PH. 1996. Comparison of A60 and three glycolipid antigens in an ELISA test for tuberculosis. Clin Microbiol Infect 2: 214-222.
132. Singh A, Crossman DK, Mai D, Guidry L, Voskuil MI, Renfrow MB, Steyn AJ. 2009. Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response. PLoS Pathog 5: e1000545.
133. Sinsimer D, Huet G, Manca C, Tsenova L, Koo MS, Kurepina N, Kana B, Mathema B, Marras SA, Kreiswirth BN, et al. 2008. The phenolic glycolipid ofMycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence. Infect Immun 76: 3027-3036.
134. Sirakova TD, Dubey VS, Deb C, Daniel J, Korotkova TA, Abomoelak B, Kolattukudy PE. 2006. Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology 152: 2717-2725.
135. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, et al. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7: 1377-1384.
136. Stanley SA, Kawate T, Iwase N, Shimizu M, Clatworthy AE, Kazyanskaya E, Sacchettini JC, Ioerger TR, Siddiqi NA, Minami S, et al. 2013. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc Natl Acad Sci 110: 11565-11570.
137. Stover KC, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
138. Sugawara I, Udagawa T, Hua SC, Reza-Gholizadeh M, Otomo K, Saito Y, Yamada H. 2002. Pulmonary granulomas of guinea pigs induced by inhalation exposure of heat-treated BCG Pasteur, purified trehalose dimycolate and methyl ketomycolate. J Med Microbiol 51: 131-137.
139. Supply P, Marceau M, Mangenot S, Roche D, Rouanet C, Khanna V, Majlessi L, Criscuolo A, Tap J, Pawlik A, et al. 2013. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat Genet 45: 172-179.
140. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, et al. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809.
141. Tsenova L, Ellison E, Harbacheuski R, Moreira AL, Kurepina N, Reed MB, Mathema B, Barry CE III, Kaplan G. 2005. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 192: 98-106.
142. Uh E, Jackson ER, San Jose G, Maddox M, Lee RE, Lee RE, Boshoff HI, Dowd CS. 2011. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg Med Chem Lett 21: 6973-6976.
143. Van Rhijn I, Ly D, Moody DB. 2013. CD1a, CD1b, and CD1c in immunity against mycobacteria. Adv Exp Med Biol 783: 181-197.
144. Vander Beken S, Al Dulayymi JR, Naessens T, Koza G, Maza-Iglesias M, Rowles R, Theunissen C, De Medts J, Lanckacker E, Baird MS, et al. 2011.Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur J Immunol 41: 450-460.
145. Vera-Cabrera L, Handzel V, Laszlo A. 1994. Development of an enzyme-linked immunosorbent assay (ELISA) combined with a streptavidin-biotin and enzyme amplification method to detect anti-2,3-di-o-acyltrehalose (DAT) antibodies in patients with tuberculosis. J Immunol Methods 177: 69-77.
146. Vilcheze C, Jacobs WR, 2007. The mechanism of isoniazid killing: Clarity through the scope of genetics. Annu Rev Microbiol 61: 35-50.
147. Vilcheze C, Baughn AD, Tufariello J, Leung LW, Kuo M, Basler CF, Alland D, Sacchettini JC, Freundlich JS, Jacobs WR. 2011. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother 55: 3889-3898.
148. Villemagne B, Crauste C, Flipo M, Baulard AR, Deprez B, Willand N. 2012. Tuberculosis: The drug development pipeline at a glance. Eur J Med Chem 51: 1-16.
149. Villeneuve C, Gilleron M, Maridonneau-Parini I, Daffe M, Astarie-Dequeker C, Etienne G. 2005. Mycobacteria use their surface-exposed glycolipids to infect human macrophages through a receptor-dependent process. J Lipid Res 46: 475-483.
150. Vir P, Gupta D, Agarwal R, Verma I. 2013. Immunomodulation of alveolar epithelial cells byMycobacterium tuberculosis phosphatidylinositol mannosides results in apoptosis. APMIS 122: 268-282.
151. Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, Schito M, Zumla A. 2013. Tuberculosis biomarkers discovery: Developments, needs, and challenges. Lancet Infect Dis 13: 362-372.
152. Walters SB, Dubnau E, Kolesnikova I, Laval F, Daffe M, Smith I. 2006. The Mycobacterium tuberculosis PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. MolMicrobiol 60: 312-330.
153. Wang F, Sambandan D, Halder R, Wang J, Batt SM, Weinrick B, Ahmad I, Yang P, Zhang Y, Kim J, et al. 2013. Identification of a small molecule with activity against drugresistant and persistent tuberculosis. Proc Natl Acad Sci 110: E2510-E2517.
154. Warrier T, Tropis M, Werngren J, Diehl A, Gengenbacher M, Schlegel B, Schade M, Oschkinat H, Daffe M, Hoffner S, et al. 2012. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob Agents Chemother 56: 1735-1743.
155. Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. 2005. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci 102: 4548-4553.
156. Willand N, Dirie B, Carette X, Bifani P, Singhal A, Desroses M, Leroux F, Willery E, Mathys V, Deprez-Poulain R, et al. 2009. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 15: 537-544.
157. Wilson R, Kumar P, Parashar V, Vilcheze C, Veyron-Churlet R, Freundlich JS, Barnes SW, Walker JR, Szymonifka MJ, Marchiano E, et al. 2013. Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat Chem Biol 9: 499-506.
158. Yang L, Sinha T, Carlson TK, Keiser TL, Torrelles JB, Schlesinger LS. 2013. Changes in the major cell envelope components of Mycobacterium tuberculosis during in vitro growth. Glycobiology 23: 926-934.
159. Yuan Y, Zhu Y, Crane DD, Barry CE III. 1998. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol Microbiol 29: 1449-1458.
160. Zhang J, Amin AG, Holemann A, Seeberger PH, Chatterjee D. 2010. Development of a plate-based scintillation proximity assay for the mycobacterial AftB enzyme involved in cell wall arabinan biosynthesis. Bioorg Med Chem 18: 7121-7131.
161. Zhang J, Angala SK, Pramanik PK, Li K, Crick DC, Liav A, Jozwiak A, Swiezewska E, Jackson M, Chatterjee D. 2011. Reconstitution of functional mycobacterial arabinosyltransferase aftc proteoliposome and assessment of decaprenylphosphorylarabinose analogues as arabinofuranosyl donors. ACS Chem Biol 6: 819-828.
162. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 6: 1043-1047.
163. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffe M. 2008. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bact 190: 5672-5680.